Development of the <sup>99m</sup>Tc-Labelled SST<sub>2</sub> Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

Development of the <sup>99m</sup>Tc-Labelled SST<sub>2</sub> Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

Broad availability and cost-effectiveness of <sup>99</sup>Mo/<sup>99m</sup>Tc generators worldwide support the use, and thus the development, of novel <sup>99m</sup>Tc-labelled radiopharmaceuticals. In recent years, preclinical and clinical developments for neuroe...

Full description

Bibliographic Details
Main Authors: Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Pharmaceutics
Subjects:
technetium-99m
somatostatin receptor antagonists
kit formulation
single dose toxicity
SPECT
radiopharmaceuticals
Online Access:https://www.mdpi.com/1999-4923/15/3/885

Internet

https://www.mdpi.com/1999-4923/15/3/885

Similar Items